病人源性头颈部黏膜恶性黑色素瘤细胞模型的构建及鉴定

doi:10.19438/j.cjoms.2017.05.002

中国口腔颌面外科杂志 ›› 2017, Vol. 15 ›› Issue (5): 388-391.doi: 10.19438/j.cjoms.2017.05.002

病人源性头颈部黏膜恶性黑色素瘤细胞模型的构建及鉴定

韩永¹，石超吉¹，周榕¹，陶文杰¹，洪多¹，李江²，孙树洋¹，张志愿¹

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科，
2.口腔病理科，上海市口腔医学重点实验室，上海 200011

收稿日期:2017-02-20 出版日期:2017-08-30 发布日期:2017-10-27
通讯作者: 张志愿，E-mail：zhzhy0502@163.com
作者简介:韩永（1989-），男，硕士，E-mail：hzwlaojiu@foxmail.com
基金资助:
国家自然科学基金（81572656）

Establishment and validation of patient derived tumor cell model in mucosal melanoma of head and neck

HAN Yong¹, SHI Chao-ji¹, ZHOU Rong¹, TAO Wen-jie¹, HONG Duo¹, LI Jiang², SUN Shu-yang¹, ZHANG Zhi-yuan¹.

1.Department of Oromaxillofacial Head and Neck Oncology,
2. Department of Oral Pathology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine;
Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2017-02-20 Online:2017-08-30 Published:2017-10-27

摘要/Abstract

摘要： 目的：构建及鉴定头颈部黏膜恶性黑色素瘤（mucosal melanoma of head and neck, HNMM）病人源性肿瘤细胞（patient derived tumor cell, PDC）模型。方法：通过肿瘤组织块原代培养、分离肿瘤细胞，利用免疫荧光染色鉴定分离的肿瘤细胞；以PDC皮下成瘤，通过组织切片染色和免疫组织化学染色对比病人原发灶和PDC成瘤组织的细胞学形态。结果：头颈黏膜恶性黑色素瘤患者移植瘤组织块分离出的细胞细胞膜和细胞质HMB-45和Melan-A免疫荧光染色呈阳性。PDC可以在裸鼠皮下成瘤，成瘤组织与患者组织细胞形态一致。结论：头颈部黏膜恶性黑色素瘤构建的PDC模型能够反映患者的组织学特征，PDC模型能够为头颈部黏膜恶性黑色素瘤的研究提供可靠的模型。

关键词: 头颈部, 黏膜恶性黑色素瘤, PDC模型, 免疫荧光染色, 皮下成瘤

Abstract: PURPOSE: To establish and validate patient derived tumor cell (PDC) model from mucosal melanoma of head and neck (HNMM). METHODS: Tumor cells derived from xenografted tumor tissue of patients with mucosal melanoma of head and neck were validated by immunofluorescence staining. Patient derived tumor cells were injected subcutaneously into nude mice. Tumor tissues originated from PDC were compared to tissue from primary tumors by H-E and immunochemistry staining. RESULTS: Immunofluorescence signal of HMB-45 and Melan-A expressed on membrane and cytoplasm of patient derived tumor cell. Patient derived tumor cell could form subcutaneous tumor in nude mice. The histology was similar between subcutaneous tumor and primary tumor under H-E and immunochemistry staining. CONCLUSIONS: Patient derived tumor cell model can be established from mucosal melanoma of head and neck and be used as a validated preclinical model for drug screening.

Key words: Head and neck, Mucosal melanoma, PDC model, Immunofluorescence staining, Subcutaneous tumor

中图分类号:

R739.5

韩永，石超吉，周榕，陶文杰，洪多，李江，孙树洋，张志愿. 病人源性头颈部黏膜恶性黑色素瘤细胞模型的构建及鉴定[J]. 中国口腔颌面外科杂志, 2017, 15(5): 388-391.

HAN Yong, SHI Chao-ji, ZHOU Rong, TAO Wen-jie, HONG Duo, LI Jiang, SUN Shu-yang, ZHANG Zhi-yuan.. Establishment and validation of patient derived tumor cell model in mucosal melanoma of head and neck[J]. China J Oral Maxillofac Surg, 2017, 15(5): 388-391.

参考文献

[1] López F, Rodrigo JP, Cardesa A, et al. Update on primary head and neck mucosal melanoma[J]. Head Neck, 2016, 38(1): 147-155.
[2] Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis [J]. Int J Cancer, 2014, 134(12): 2961-2971.
[3] Tanaka N, Mimura M, Ogi K, et al. Primary malignant melanoma of the oral cavity: assessment of outcome from the clinical records of 35 patients[J]. Int J Oral Maxillofac Surg, 2004, 33(8): 761-765.
[4] Tacastacas JD, Bray J, Cohen YK, et al. Update on primary mucosal melanoma[J]. J Am Acad Dermatol, 2014, 71(2): 366-375.
[5] Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma[J]. JAMA, 2011, 305(22): 2327-2334.
[6] Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma [J]. Clin Cancer Res, 2011, 17(7): 1684-1691.
[7] Lian B, Cui CL, Zhou L, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients [J]. Ann Oncol, 2017, 28(4): 868-873.
[8] Hicks MJ, Flaitz CM. Oral mucosal melanoma: epidemiology and pathobiology [J]. Oral Oncol, 2000, 36(2): 152-169.
[9] Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification [J]. J Clin Oncol, 2011, 29(21): 2904-2909.
[10] Chang KW, Lin SC, Chao SY, et al. Establishment and characterization of an oral melanoma cell line (ME)[J]. Oral Oncol, 2001, 37(3): 301-307.
[11] Lourenco SV, Bologna SB, Hsieh R, et al. Establishment and characterization of an oral mucosal melanoma cell line (MEMO) derived from a longstanding primary oral melanoma [J]. Am J Dermatopathol, 2013, 35(2): 248-251.
[12] Selvan SR, Carbonell DJ, Fowler AW, et al. Establishment of stable cell lines for personalized melanoma cell vaccine [J]. Melanoma Res, 2010, 20(4): 280-292.
[13] Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds[J]. Cell, 2016, 167(1): 260-274.e222.
[14] Gao Q, Wang ZC, Duan M, et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents [J]. Gastroenterology, 2017, 152(1): 232-242.e234.
[15] Arena S, Siravegna G, Mussolin B, et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations [J]. Sci Transl Med, 2016, 8(324): 324ra314.
[16] Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery [J]. Nat Rev Drug Discov, 2009, 8(10): 806-823.
[17] Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy [J]. Trends Biotechnol, 2013, 31(6): 347-354.
[18] Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer [J]. Science, 2014, 346(6216): 1480-1486.

病人源性头颈部黏膜恶性黑色素瘤细胞模型的构建及鉴定

Establishment and validation of patient derived tumor cell model in mucosal melanoma of head and neck

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩林孜, 周建华, 赵谦, 董磊, 陈正岗, 邱建忠, 袁荣涛. 肿瘤相关成纤维细胞对头颈部鳞状细胞癌肿瘤浸润免疫细胞的调控作用及机制探讨[J]. 中国口腔颌面外科杂志, 2023, 21(2): 119-124.
[2]	邱银秀, 代天国, 徐波, 程进强, 刘忠龙. 重症口腔颌面头颈部多间隙感染临床分类探讨[J]. 中国口腔颌面外科杂志, 2023, 21(2): 125-130.
[3]	陈伟良. 延长垂直下斜方肌岛状肌皮瓣修复重建大型头颈部缺损[J]. 中国口腔颌面外科杂志, 2023, 21(1): 1-10.
[4]	李雪儿, 王正业, 买买提吐逊·吐尔地. 基于影像组学鉴定头颈部鳞状细胞癌患者HPV状态：诊断性meta分析[J]. 中国口腔颌面外科杂志, 2023, 21(1): 69-74.
[5]	龚霞, 李佳, 熊屏, 丁昂昂. 头颈部脉管肿瘤的超声诊断[J]. 中国口腔颌面外科杂志, 2022, 20(6): 521-526.
[6]	龚霞, 李佳, 熊屏, 丁昂昂. 头颈部脉管畸形的超声诊断[J]. 中国口腔颌面外科杂志, 2022, 20(5): 417-421.
[7]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.
[8]	王灿, 张春叶, 陶晓峰, 王博成, 朱凌. 29例头颈部炎性肌纤维母细胞肿瘤的CT及MRI影像学特征分析[J]. 中国口腔颌面外科杂志, 2022, 20(5): 494-499.
[9]	徐卫靖, 高振杰, 付坤, 高宁, 程龙, 何巍. 33例头颈部胚胎型横纹肌肉瘤临床与病理特点分析[J]. 中国口腔颌面外科杂志, 2022, 20(3): 292-297.
[10]	陈一铭, Ahmed, 季彤, 任振虎. 101例头颈部横纹肌肉瘤临床、病理及预后分析[J]. 中国口腔颌面外科杂志, 2022, 20(2): 146-150.
[11]	樊文慧, 石慧烽, 涂文勇. 2种不同形变配准软件在头颈部勾画中的作用评价[J]. 中国口腔颌面外科杂志, 2021, 19(6): 517-524.
[12]	劳峥, 毕帆, 樊文慧, 胡海生, 涂文勇, 石慧烽. 去伪影算法对头颈部肿瘤患者钛板植入术后放疗的剂量影响[J]. 中国口腔颌面外科杂志, 2021, 19(3): 248-252.
[13]	戴振霖, 艾哈迈德·阿德热罕穆, 陈一铭, 汪轶, 季彤. 新辅助化疗治疗头颈部骨肉瘤单中心临床效果回顾[J]. 中国口腔颌面外科杂志, 2021, 19(2): 132-137.
[14]	何悦, 蒋灿华, 侯劲松, 王慧明, 彭歆, 刘冰, 李劲松, 郑磊, 徐中飞, 吴煜农, 胡镜宙, 秦兴军, 艾松涛, 周辉红, 李春洁, 张世周, 王军, 李晓光, 刘忠龙, 祝奉硕. 穿支皮瓣修复口腔颌面-头颈部缺损专家共识[J]. 中国口腔颌面外科杂志, 2020, 18(5): 385-389.
[15]	毛蓓茜, 黄瑶, 吴薇, 罗吴亮, 徐兵, 寿宇雁. 健康教育路径在口腔颌面头颈部肿瘤经皮内镜胃造瘘患者中的临床应用评价[J]. 中国口腔颌面外科杂志, 2020, 18(5): 442-446.